Journal_110217

Nat. Med.
SAMHD1 is a biomarker for cytarabine response and a therapeutic target in acute myeloid leukemia

Constanze Schneider1,17, Thomas Oellerich2–4,17, Hanna-Mari Baldauf1,5,17, Sarah-Marie Schwarz1,17, Dominique Thomas6, Robert Flick7, Hanibal Bohnenberger8, Lars Kaderali9, Lena Stegmann1, Anjali Cremer2, Margarethe Martin1, Julian Lohmeyer2, Martin Michaelis10, Veit Hornung11,12, Christoph Schliemann13, Wolfgang E Berdel13, Wolfgang Hartmann14, Eva Wardelmann14, Federico Comoglio3, Martin-Leo Hansmann15, Alexander F Yakunin7, Gerd Geisslinger6,16, Philipp Ströbel8, Nerea Ferreirós6, Hubert Serve2,4,
Oliver T Keppler1,5 & Jindrich Cinatl Jr1